Siemens Healthineers and AiM Medical Robotics are collaborating to integrate AiM’s robotic neurosurgery system with Siemens Healthineers’ magnetic resonance imaging scanners.
AiM is developing a portable robotic surgery system for use in neurostimulation lead placement, biopsies, tumor and epilepsy ablation, and drug delivery.
The companies have agreed to implement an interface that would allow Siemens Healthineers’ Magnetom MRI scanners to connect with AiM’s platform to guide procedures, AiM said this week.
AiM last year closed an $8.1 million Series A financing round to fund a first-in-human clinical study and accelerate product development.
The Worcester, Massachusetts-based company partnered with Brigham and Women’s Hospital and the Surgical Navigation and Robotics Laboratory at Harvard Medical School in 2024 to study its robot for deep brain stimulation to treat Parkinson’s disease.
Procept advances prostate cancer study
Procept BioRobotics said Thursday it finished enrolling patients in a randomized study comparing its aquablation therapy to prostate gland removal.
Radical prostatectomy, where the surgeon removes the entire gland and some of the tissue around it, is the main type of surgery for prostate cancer.
Procept’s aquablation procedure, which uses pressurized fluid to cut tissue, is cleared by the Food and Drug Administration to treat benign prostatic hyperplasia, or enlarged prostate.
Procept said it expects to present primary endpoint results for the 280-patient WATER IV study at the American Urological Association meeting in spring 2027.
The company also said it received FDA approval for a second randomized study comparing aquablation to active surveillance in men with lower-risk prostate cancer. The study of up to 333 patients will evaluate whether aquablation may be an earlier treatment option before the disease progresses further.
